Andrew Berchuck

Overview:

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Positions:

James M. Ingram Distinguished Professor of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Chief of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1980

Case Western Reserve University

Grants:

A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities

Administered By
Population Health Sciences
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Endometrial Cancer TCGA Project

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
MD Anderson Cancer Center
Role
Principal Investigator
Start Date
End Date

TGCA Purchase Order

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
Leidos Biomedical Research, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.

Growth factors in tumor environments are regulators of cell survival and metastasis. Here, we reveal the dichotomy between TGF-β superfamily growth factors BMP and TGF-β/activin and their downstream SMAD effectors. Gene expression profiling uncovers SOX2 as a key contextual signaling node regulated in an opposing manner by BMP2, -4, and -9 and TGF-β and activin A to impact anchorage-independent cell survival. We find that SOX2 is repressed by BMPs, leading to a reduction in intraperitoneal tumor burden and improved survival of tumor-bearing mice. Repression of SOX2 is driven by SMAD1-dependent histone H3K27me3 recruitment and DNA methylation at SOX2's promoter. Conversely, TGF-β, which is elevated in patient ascites, and activin A can promote SOX2 expression and anchorage-independent survival by SMAD3-dependent histone H3K4me3 recruitment. Our findings identify SOX2 as a contextual and contrastingly regulated node downstream of TGF-β members controlling anchorage-independent survival and metastasis in ovarian cancers.
Authors
Shonibare, Z; Monavarian, M; O'Connell, K; Altomare, D; Shelton, A; Mehta, S; Jaskula-Sztul, R; Phaeton, R; Starr, MD; Whitaker, R; Berchuck, A; Nixon, AB; Arend, RC; Lee, NY; Miller, CR; Hempel, N; Mythreye, K
MLA Citation
Shonibare, Zainab, et al. “Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.Cell Rep, vol. 40, no. 4, July 2022, p. 111066. Pubmed, doi:10.1016/j.celrep.2022.111066.
URI
https://scholars.duke.edu/individual/pub1529936
PMID
35905726
Source
pubmed
Published In
Cell Reports
Volume
40
Published Date
Start Page
111066
DOI
10.1016/j.celrep.2022.111066

G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment.

Ovarian cancer (OC) is the most lethal gynecological malignancy, with aggressive metastatic disease responsible for the majority of OC-related deaths. In particular, OC tumors preferentially metastasize to and proliferate rapidly in the omentum. Here, we show that metastatic OC cells experience increased oxidative stress in the omental microenvironment. Metabolic reprogramming, including upregulation of the pentose phosphate pathway (PPP), a key cellular redox homeostasis mechanism, allows OC cells to compensate for this challenge. Inhibition of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, reduces tumor burden in pre-clinical models of OC, suggesting that this adaptive metabolic dependency is important for OC omental metastasis.
Authors
Bose, S; Huang, Q; Ma, Y; Wang, L; Rivera, GO; Ouyang, Y; Whitaker, R; Gibson, RA; Kontos, CD; Berchuck, A; Previs, RA; Shen, X
MLA Citation
Bose, Shree, et al. “G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment.Cell Rep, vol. 39, no. 13, June 2022, p. 111012. Pubmed, doi:10.1016/j.celrep.2022.111012.
URI
https://scholars.duke.edu/individual/pub1525423
PMID
35767962
Source
pubmed
Published In
Cell Reports
Volume
39
Published Date
Start Page
111012
DOI
10.1016/j.celrep.2022.111012

Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.

Hypoxia, a driver of tumor growth and metastasis, regulates angiogenic pathways that are targets for vessel normalization and ovarian cancer management. However, toxicities and resistance to anti-angiogenics can limit their use making identification of new targets vital. Inhibin, a heteromeric TGFβ ligand, is a contextual regulator of tumor progression acting as an early tumor suppressor, yet also an established biomarker for ovarian cancers. Here, we find that hypoxia increases inhibin levels in ovarian cancer cell lines, xenograft tumors, and patients. Inhibin is regulated primarily through HIF-1, shifting the balance under hypoxia from activins to inhibins. Hypoxia regulated inhibin promotes tumor growth, endothelial cell invasion and permeability. Targeting inhibin in vivo through knockdown and anti-inhibin strategies robustly reduces permeability in vivo and alters the balance of pro and anti-angiogenic mechanisms resulting in vascular normalization. Mechanistically, inhibin regulates permeability by increasing VE-cadherin internalization via ACVRL1 and CD105, a receptor complex that we find to be stabilized directly by inhibin. Our findings demonstrate direct roles for inhibins in vascular normalization via TGF-β receptors providing new insights into the therapeutic significance of inhibins as a strategy to normalize the tumor vasculature in ovarian cancer.
Authors
Horst, B; Pradhan, S; Chaudhary, R; Listik, E; Quintero-Macias, L; Choi, AS; Southard, M; Liu, Y; Whitaker, R; Hempel, N; Berchuck, A; Nixon, AB; Lee, NY; Henis, YI; Mythreye, K
MLA Citation
Horst, Ben, et al. “Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.Commun Biol, vol. 5, no. 1, June 2022, p. 536. Pubmed, doi:10.1038/s42003-022-03495-6.
URI
https://scholars.duke.edu/individual/pub1523721
PMID
35654828
Source
pubmed
Published In
Communications Biology
Volume
5
Published Date
Start Page
536
DOI
10.1038/s42003-022-03495-6

Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.

<h4>Background</h4>Tumor-infiltrating lymphocytes (TIL) confer a survival benefit among patients with ovarian cancer; however, little work has been conducted in racially diverse cohorts.<h4>Methods</h4>The current study investigated racial differences in the tumor immune landscape and survival of age- and stage-matched non-Hispanic Black and non-Hispanic White women with high-grade serous ovarian carcinoma (HGSOC) enrolled in two population-based studies (n = 121 in each racial group). We measured TILs (CD3+), cytotoxic T cells (CD3+CD8+), regulatory T cells (CD3+FoxP3+), myeloid cells (CD11b+), and neutrophils (CD11b+CD15+) via multiplex immunofluorescence. Multivariable Cox proportional hazard regression was used to estimate the association between immune cell abundance and survival overall and by race.<h4>Results</h4>Overall, higher levels of TILs, cytotoxic T cells, myeloid cells, and neutrophils were associated with better survival in the intratumoral and peritumoral region, irrespective of tissue compartment (tumor, stroma). Improved survival was noted for T-regulatory cells in the peritumoral region and in the stroma of the intratumoral region, but no association for intratumoral T-regulatory cells. Despite similar abundance of immune cells across racial groups, associations with survival among non-Hispanic White women were consistent with the overall findings, but among non-Hispanic Black women, most associations were attenuated and not statistically significant.<h4>Conclusions</h4>Our results add to the existing evidence that a robust immune infiltrate confers a survival advantage among women with HGSOC; however, non-Hispanic Black women may not experience the same survival benefit as non-Hispanic White women with HGSOC.<h4>Impact</h4>This study contributes to our understanding of the immunoepidemiology of HGSOC in diverse populations.
Authors
Peres, LC; Colin-Leitzinger, C; Sinha, S; Marks, JR; Conejo-Garcia, JR; Alberg, AJ; Bandera, EV; Berchuck, A; Bondy, ML; Christensen, BC; Cote, ML; Doherty, JA; Moorman, PG; Peters, ES; Moran Segura, C; Nguyen, JV; Schwartz, AG; Terry, PD; Wilson, CM; Fridley, BL; Schildkraut, JM
MLA Citation
Peres, Lauren C., et al. “Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, vol. 31, no. 5, May 2022, pp. 1006–16. Epmc, doi:10.1158/1055-9965.epi-21-1334.
URI
https://scholars.duke.edu/individual/pub1512202
PMID
35244678
Source
epmc
Published In
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Volume
31
Published Date
Start Page
1006
End Page
1016
DOI
10.1158/1055-9965.epi-21-1334

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.

Studies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC. Women with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated. A total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96-1.01 and 0.98; 95%CI 0.95-1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43-12.73) and OS (HR 1.69, 95%CI 0.56-5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36-5.81) and OS (HR 6.62, 95%CI 2.45-17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85). Advanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS. 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival.
Authors
Wohlmuth, C; Djedovic, V; Kjaer, SK; Jensen, A; Glasspool, R; Roxburgh, P; DeFazio, A; Johnatty, SE; Webb, PM; Modugno, F; Lambrechts, D; Schildkraut, JM; Berchuck, A; Thomsen, LCV; Bjorge, L; Høgdall, E; Høgdall, CK; Goode, EL; Winham, SJ; Matsuo, K; Karlan, BY; Lester, J; Goodman, MT; Thompson, PJ; Pejovic, T; Riggan, MJ; Lajkosz, K; Tone, A; May, T
MLA Citation
Wohlmuth, Christoph, et al. “CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.Cancers, vol. 14, no. 8, Apr. 2022, p. 1954. Epmc, doi:10.3390/cancers14081954.
URI
https://scholars.duke.edu/individual/pub1518431
PMID
35454861
Source
epmc
Published In
Cancers
Volume
14
Published Date
Start Page
1954
DOI
10.3390/cancers14081954

Research Areas:

3' Untranslated Regions
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
5-Lipoxygenase-Activating Proteins
ABO Blood-Group System
ATP-Binding Cassette, Sub-Family B, Member 1
Acetaminophen
Actins
Actomyosin
Actuarial Analysis
Adaptor Proteins, Signal Transducing
Adenocarcinoma
Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Adnexa Uteri
Adnexal Diseases
Adolescent
Adult
African Americans
African Continental Ancestry Group
Age Distribution
Age Factors
Age of Onset
Aged
Aged, 80 and over
Alcohol Dehydrogenase
Algorithms
Alkylating Agents
Alleles
Alternative Splicing
Americas
Amidohydrolases
Amino Acid Sequence
Aminopeptidases
Amnion
Analysis of Variance
Anemia
Aneuploidy
Angiogenic Proteins
Animals
Anthropometry
Anti-Inflammatory Agents, Non-Steroidal
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antidepressive Agents
Antigens, CD
Antigens, CD31
Antigens, CD45
Antigens, CD80
Antigens, Tumor-Associated, Carbohydrate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Apolipoprotein A-I
Apoptosis
Apoptosis Regulatory Proteins
Arylamine N-Acetyltransferase
Ascites
Ascitic Fluid
Autophagy
Azacitidine
B7-1 Antigen
BRCA1 Protein
BRCA2 Protein
Base Sequence
Bayes Theorem
Binding Sites
Biopsy
Biopsy, Needle
Blood Coagulation
Blood Coagulation Disorders
Blood Coagulation Tests
Blood Loss, Surgical
Blood Transfusion
Blotting, Northern
Blotting, Southern
Blotting, Western
Body Height
Body Mass Index
Bone Marrow Transplantation
Brachytherapy
Brain Neoplasms
Breast
Breast Neoplasms
CA-125 Antigen
Cadherins
Caloric Restriction
Cancer
Carbon-Nitrogen Ligases
Carboplatin
Carcinoembryonic Antigen
Carcinoma
Carcinoma in Situ
Carcinoma, Adenoid Cystic
Carcinoma, Endometrioid
Carcinoma, Papillary
Carcinoma, Signet Ring Cell
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Carcinosarcoma
Carrier Proteins
Case-Control Studies
Caspase 3
Caspase 8
Catalytic Domain
Cell Adhesion
Cell Culture Techniques
Cell Cycle
Cell Cycle Proteins
Cell Division
Cell Growth Processes
Cell Line
Cell Line, Transformed
Cell Line, Tumor
Cell Lineage
Cell Movement
Cell Proliferation
Cell Shape
Cell Survival
Cell Transformation, Neoplastic
Cells, Cultured
Cervix Uteri
Cesarean Section
Chemotherapy
Chemotherapy, Adjuvant
Chi-Square Distribution
Chickens
Child
Child, Preschool
Chloramphenicol O-Acetyltransferase
Choriocarcinoma
Chorionic Gonadotropin
Chromatin
Chromatography, Affinity
Chromatography, Liquid
Chromium
Chromium Compounds
Chromosome Aberrations
Chromosome Deletion
Chromosome Mapping
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 18
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 2
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9
Cisplatin
Clinical Competence
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clone Cells
Cloning, Molecular
Cluster Analysis
Codon
Cohort Studies
Coitus
Colectomy
Collagen
Colon
Colon, Sigmoid
Colonic Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Combined Modality Therapy
Comparative Effectiveness Research
Comparative Genomic Hybridization
Compliance
Condylomata Acuminata
Confidence Intervals
Confounding Factors (Epidemiology)
Contraception
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Cooperative Behavior
Cost-Benefit Analysis
Counseling
CpG Islands
Culture Media
Cyclin E
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases
Cyclins
Cyclophosphamide
Cystadenocarcinoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
Cystadenoma, Mucinous
Cystadenoma, Serous
Cysts
Cytochrome P-450 CYP1A1
Cytochrome P-450 CYP3A
Cytokines
Cytostatic Agents
DNA
DNA (Cytosine-5-)-Methyltransferase
DNA (Cytosine-5-)-Methyltransferases
DNA Copy Number Variations
DNA Damage
DNA Fingerprinting
DNA Helicases
DNA Ligases
DNA Methylation
DNA Mismatch Repair
DNA Mutational Analysis
DNA Polymerase II
DNA Primers
DNA Repair
DNA, Complementary
DNA, Neoplasm
DNA, Satellite
DNA, Single-Stranded
DNA-Binding Proteins
Dactinomycin
Data Collection
Decision Support Techniques
Decision Trees
Deoxyribonucleases, Type II Site-Specific
Depression, Chemical
Dermatologic Surgical Procedures
Developed Countries
Diacylglycerol Kinase
Diagnosis, Differential
Diet
Dietary Supplements
Diffusion of Innovation
Dihydrouracil Dehydrogenase (NADP)
Dinoprostone
Diploidy
Discriminant Analysis
Disease Models, Animal
Disease Progression
Disease-Free Survival
Diseases
Dormancy
Dosage Compensation, Genetic
Dose-Response Relationship, Drug
Down-Regulation
Doxorubicin
Drug Administration Schedule
Drug Combinations
Drug Design
Drug Resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Synergism
E2F Transcription Factors
Early Detection of Cancer
Education, Medical, Graduate
Eflornithine
Eggs
Electrophoresis, Polyacrylamide Gel
Endometrial Hyperplasia
Endometrial Neoplasms
Endometriosis
Endometrium
Endosomal Sorting Complexes Required for Transport
Environmental Exposure
Enzyme Induction
Enzyme Inhibitors
Enzyme-Linked Immunosorbent Assay
Epidermal Growth Factor
Epigenesis, Genetic
Epigenomics
Epithelial Cells
Epithelium
Epitopes
Epoxide Hydrolases
Estradiol
Estrogen Antagonists
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogen Replacement Therapy
Estrogens
Ethics, Medical
Ethnic Groups
Etoposide
Europe
European Continental Ancestry Group
Evaluation Studies as Topic
Exome
Exons
Extracellular Space
Factor IX
Fallopian Tube Neoplasms
Fallopian Tubes
Family planning
Fatigue
Fellowships and Scholarships
Female
Fetal Diseases
Fibrin Fibrinogen Degradation Products
Fibroblast Growth Factor 2
Fibroblast Growth Factors
Fibroblasts
Fibronectins
Fistula
Flow Cytometry
Fluorescent Antibody Technique
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Folate Receptor 1
Folate Receptors, GPI-Anchored
Folic Acid
Follow-Up Studies
Forecasting
Formaldehyde
Frozen Sections
G1 Phase
GPI-Linked Proteins
GTP Phosphohydrolases
GTP-Binding Proteins
Galectin 1
Galectin 3
Gastrointestinal Diseases
Gene Amplification
Gene Deletion
Gene Dosage
Gene Expression
Gene Expression Profiling
Gene Expression Regulation
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Gene Frequency
Gene Silencing
Gene Transfer Techniques
Gene-Environment Interaction
Genes, BRCA1
Genes, BRCA2
Genes, Neoplasm
Genes, Tumor Suppressor
Genes, cdc
Genes, fms
Genes, p16
Genes, p53
Genes, ras
Genetic Association Studies
Genetic Heterogeneity
Genetic Linkage
Genetic Loci
Genetic Markers
Genetic Predisposition to Disease
Genetic Testing
Genetic Therapy
Genetic Variation
Genetics
Genital Diseases, Female
Genital Neoplasms, Female
Genome, Human
Genome-Wide Association Study
Genomic Imprinting
Genomic Instability
Genomics
Genotype
Germ-Line Mutation
Glycoproteins
Gonadotropins
Granulocyte Colony-Stimulating Factor
Gravity Suits
Great Britain
Green Fluorescent Proteins
Growth Inhibitors
Growth Substances
Gynecologic Surgical Procedures
Gynecology
Half-Life
Haplotypes
HeLa Cells
Head and Neck Neoplasms
Health Care Costs
Health Planning Guidelines
Health Resources
Hemagglutinins
Hemorrhage
Heparin
Hepatocyte Nuclear Factor 1-beta
Heterocyclic Compounds with 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Heterozygote
Histones
Homeodomain Proteins
Homozygote
Hormone Replacement Therapy
Hormones
Humans
Hybrid Cells
Hydatidiform Mole
Hydrolysis
Hyperthermia, Induced
Hysterectomy
Image Processing, Computer-Assisted
Immunity
Immunoassay
Immunoblotting
Immunoenzyme Techniques
Immunohistochemistry
Immunologic Factors
Immunoradiometric Assay
Immunosuppressive Agents
Immunotherapy
Immunotoxins
In Situ Hybridization
Incidence
Infant
Infant, Newborn
Infection
Inflammation
Infusions, Parenteral
Injections, Intramuscular
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Integrins
Intercellular Signaling Peptides and Proteins
Interferon-gamma
Interleukin-1
Interleukin-18
Interleukin-1alpha
Interleukin-6
International Agencies
International Cooperation
Internship and Residency
Interviews as Topic
Intracellular Signaling Peptides and Proteins
Intraoperative Complications
Introns
Kaplan-Meier Estimate
Keratins
Ki-67 Antigen
Kidney Diseases
Kinetics
Laminin
Laparoscopy
Laparotomy
Leiomyoma
Leiomyosarcoma
Length of Stay
Leucine Zippers
Leukocyte Common Antigens
Life Expectancy
Life Tables
Linear Models
Linkage Disequilibrium
Liver Diseases
Logistic Models
Longitudinal Studies
Loss of Heterozygosity
Lovastatin
Luciferases
Luminescent Proteins
Lung Diseases
Lung Neoplasms
Lymph Node Excision
Lymph Nodes
Lymphatic Diseases
Lymphatic Metastasis
Lymphedema
Lymphocyte Activation
Lymphocytes
Lymphocytes, Tumor-Infiltrating
Lysophospholipids
MAP Kinase Kinase 4
MAP Kinase Signaling System
Macaca fascicularis
Macrophage Colony-Stimulating Factor
Magnetics
Male
Mammary Neoplasms, Experimental
Marketing
Markov Chains
Matrix Metalloproteinase 1
Maximum Tolerated Dose
Medical History Taking
Medical Oncology
Medicine
Mefenamic Acid
Membrane Glycoproteins
Membrane Proteins
Membrane Transport Proteins
Menarche
Menopause
Menstrual Cycle
Menstruation Disturbances
Meta-Analysis as Topic
Metabolic Clearance Rate
Methods
Methotrexate
Methylation
Methylenetetrahydrofolate Dehydrogenase (NADP)
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
Microarray Analysis
Microfilament Proteins
Micromanipulation
Microsatellite Instability
Microsatellite Repeats
Microscopy, Atomic Force
Microscopy, Confocal
Microscopy, Electron
Microspheres
Middle Aged
Mitochondrial Proteins
Mitosis
Mitotic Index
Mixed Tumor, Mesodermal
Mixed Tumor, Mullerian
Models, Biological
Models, Economic
Models, Genetic
Models, Statistical
Molecular Conformation
Molecular Sequence Data
Molecular Targeted Therapy
Molecular Weight
Morbidity
Mucin-1
Mullerian Ducts
Multicenter Studies as Topic
Multivariate Analysis
Muscle, Skeletal
MutS Homolog 2 Protein
Mutagenesis, Insertional
Mutation
Mycobacterium bovis
Myelin Proteins
Myelin and Lymphocyte-Associated Proteolipid Proteins
Myometrium
Myosin Type II
N-Acetylgalactosaminyltransferases
NAD(P)H Dehydrogenase (Quinone)
NF-kappa B
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Proteins
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Transplantation
Neoplasm, Residual
Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Multiple Primary
Neoplasms, Second Primary
Neoplastic Stem Cells
Neoplastic Syndromes, Hereditary
Neovascularization, Pathologic
Nerve Tissue Proteins
Neural Networks (Computer)
Neuropeptides
Neutropenia
Nicotinic Acids
North America
North Carolina
Nuclear Proteins
Nuclear Receptor Co-Repressor 1
Nuclear Receptor Co-Repressor 2
Nucleic Acid Heteroduplexes
Nucleic Acid Hybridization
Nutrition Disorders
Obesity
Observer Variation
Odds Ratio
Oligodeoxyribonucleotides
Oligonucleotide Array Sequence Analysis
Oligonucleotide Probes
Omentum
Oncogene Proteins, Viral
Oncogenes
Oncology Service, Hospital
Ornithine Decarboxylase
Ovarian Cysts
Ovarian Diseases
Ovarian Neoplasms
Ovariectomy
Ovary
Oviducts
Ovulation
Oxytocin
P-Glycoprotein
PTEN Phosphohydrolase
Paclitaxel
Pain, Postoperative
Palliative Care
Papillomaviridae
Paraffin Embedding
Parity
Patient Acceptance of Health Care
Patient Selection
Pedigree
Pelvic Exenteration
Pelvic Neoplasms
Pelvis
Peptide Elongation Factor Tu
Peptide Termination Factors
Peptides
Peripheral Nervous System Diseases
Peritoneal Cavity
Peritoneal Diseases
Peritoneal Lavage
Peritoneal Neoplasms
Peritoneum
Peritonitis, Tuberculous
Pharmacogenetics
Phenotype
Phosphates
Phosphatidate Phosphatase
Phosphatidylinositol 3-Kinases
Phosphoproteins
Phosphoric Monoester Hydrolases
Phosphorus Radioisotopes
Phosphorylation
Physical Examination
Pilot Projects
Piperidines
Placenta Accreta
Platelet Endothelial Cell Adhesion Molecule-1
Platelet-Derived Growth Factor
Platinum
Platinum Compounds
Ploidies
Pneumoperitoneum
Point Mutation
Poly(ADP-ribose) Polymerases
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Polymorphism, Single Nucleotide
Polymorphism, Single-Stranded Conformational
Population Dynamics
Population Surveillance
Postmenopause
Postoperative Complications
Postoperative Period
Powders
Practice Guidelines as Topic
Prealbumin
Precancerous Conditions
Precipitin Tests
Predictive Value of Tests
Pregnancy
Pregnancy Complications
Pregnancy Tests
Pregnancy Trimester, Second
Premenopause
Prenatal Diagnosis
Preoperative Care
Prevalence
Principal Component Analysis
Probability
Progesterone
Progestins
Prognosis
Proliferating Cell Nuclear Antigen
Promoter Regions, Genetic
Proportional Hazards Models
Prospective Studies
Prostaglandins
Prostaglandins E
Prostatic Neoplasms
Protamine Kinase
Protective Agents
Protein Array Analysis
Protein Isoforms
Protein Kinase C
Protein Kinase C-delta
Protein Kinase Inhibitors
Protein Precursors
Protein Processing, Post-Translational
Protein Structure, Tertiary
Protein Tyrosine Phosphatases
Protein-Serine-Threonine Kinases
Protein-Tyrosine Kinases
Proteins
Proteoglycans
Proteolipids
Proteomics
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myb
Proto-Oncogene Proteins pp60(c-src)
Proto-Oncogenes
Purines
Pyrimidines
Quality Control
Quality of Life
Quality-Adjusted Life Years
Quantitative Trait Loci
Questionnaires
Quinone Reductases
RNA
RNA Splicing
RNA, Antisense
RNA, Messenger
RNA, Neoplasm
RNA, Small Interfering
RNA, Untranslated
ROC Curve
Radiation Injuries
Radioimmunoassay
Radioimmunoprecipitation Assay
Radiopharmaceuticals
Radiotherapy
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, IGF Type 2
Receptor, erbB-2
Receptors, Androgen
Receptors, Calcitriol
Receptors, Cell Surface
Receptors, Estrogen
Receptors, Growth Factor
Receptors, Interleukin-1
Receptors, Interleukin-2
Receptors, Laminin
Receptors, Progesterone
Receptors, Transforming Growth Factor beta
Receptors, Tumor Necrosis Factor
Reconstructive Surgical Procedures
Rectus Abdominis
Recurrence
Reference Values
Registries
Regression Analysis
Remission Induction
Reoperation
Repetitive Sequences, Amino Acid
Repetitive Sequences, Nucleic Acid
Repressor Proteins
Reproducibility of Results
Reproductive History
Retinoblastoma Protein
Retirement
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Ricin
Risk
Risk Assessment
Risk Factors
Risk Reduction Behavior
Robotics
SEER Program
Sarcoma
Second-Look Surgery
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Sequence Analysis, DNA
Sequence Deletion
Serpins
Signal Transduction
Skin
Societies, Medical
Societies, Scientific
Socioeconomic Factors
Solubility
Specialization
Spheroids, Cellular
Staining and Labeling
Statistics, Nonparametric
Staurosporine
Sterilization, Tubal
Stimulation, Chemical
Stromal Cells
Sulfites
Surgical Flaps
Surgical Wound Dehiscence
Surgical Wound Infection
Surveys and Questionnaires
Survival
Survival Analysis
Survival Rate
Survivors
Sutures
T-Lymphocytes, Regulatory
TNF-Related Apoptosis-Inducing Ligand
Talc
Tamoxifen
Tandem Mass Spectrometry
Taxoids
Telomerase
Telomere
Terminal Care
Testis
Tetradecanoylphorbol Acetate
Tetrahydronaphthalenes
Therapies, Investigational
Thiazoles
Thigh
Thioguanine
Thiophenes
Thiotepa
Thrombocytosis
Thrombophlebitis
Thrombosis
Thrombospondin 1
Thymidine
Thymidylate Synthase
Time Factors
Tissue Array Analysis
Tissue Distribution
Tissue Embedding
Tissue Fixation
Tomography, Emission-Computed
Tomography, X-Ray Computed
Trans-Activators
Transcription Factors
Transcription, Genetic
Transcriptional Activation
Transfection
Transforming Growth Factor alpha
Transforming Growth Factor beta
Transforming Growth Factor beta1
Transforming Growth Factors
Transplantation, Autologous
Treatment Outcome
Tretinoin
Trinucleotide Repeats
Tritium
Trophoblastic Neoplasms
Tumor Cells, Cultured
Tumor Markers, Biological
Tumor Necrosis Factor-alpha
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
United Kingdom
United States
Up-Regulation
Urologic Diseases
Utah
Uterine Cervical Diseases
Uterine Cervical Incompetence
Uterine Cervical Neoplasms
Uterine Hemorrhage
Uterine Neoplasms
Uterine Rupture
Uterus
Vagina
Vaginal Fistula
Vaginal Neoplasms
Vaginal Smears
Vanadates
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Venous Thrombosis
Vincristine
Vulva
Vulvar Neoplasms
Wound Healing
X Chromosome
X-Linked Inhibitor of Apoptosis Protein
Xenobiotics
YY1 Transcription Factor
Young Adult
alpha-Fetoproteins
bcl-Associated Death Protein
ras Proteins
rho GTP-Binding Proteins
src-Family Kinases